.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Beclomethasone dipropionate - Generic Drug Details

« Back to Dashboard
Beclomethasone dipropionate is the generic ingredient in ten branded drugs marketed by Teva Branded Pharm, Schering, and Glaxosmithkline, and is included in ten NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has thirty-one patent family members in fifteen countries.

There are twenty drug master file entries for beclomethasone dipropionate. Three suppliers are listed for this compound.

Summary for Generic Name: beclomethasone dipropionate

Tradenames:10
Patents:3
Applicants:3
NDAs:10
Drug Master File Entries: see list20
Suppliers / Packaging: see list3
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices

Pharmacology for Ingredient: beclomethasone dipropionate

Clinical Trials for: beclomethasone dipropionate

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline
BECLOVENT
beclomethasone dipropionate
AEROSOL, METERED;INHALATION018153-001Approved Prior to Jan 1, 1982DISCNNo
Schering
VANCENASE AQ
beclomethasone dipropionate monohydrate
SPRAY, METERED;NASAL020469-001Jun 26, 1996DISCNNo
Teva Branded Pharm
QNASL
beclomethasone dipropionate
AEROSOL, METERED;NASAL202813-001Mar 23, 2012RXYes7,780,038Jan 24, 2027Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: beclomethasone dipropionate

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering
VANCENASE
beclomethasone dipropionate
AEROSOL, METERED;NASAL018521-001Approved Prior to Jan 1, 19824,414,209<disabled>
Glaxosmithkline
BECONASE
beclomethasone dipropionate
AEROSOL, METERED;NASAL018584-001Approved Prior to Jan 1, 19824,364,923<disabled>
Teva Branded Pharm
QNASL
beclomethasone dipropionate
AEROSOL, METERED;NASAL202813-002Dec 17, 20145,776,432<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: beclomethasone dipropionate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,346,232 Method of forming conductive lines<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: beclomethasone dipropionate

Country Document Number Estimated Expiration
United Kingdom2320489<disabled in preview>
Austria114112<disabled in preview>
Japan2769925<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc